General
Preferred name
ZOMEPIRAC
Synonyms
ZOMEPIRAC SODIUM ()
MCN-2783-21-98 ()
Zomax ()
McN-2783-21-98 ()
Zomepirac sodium salt ()
Zomepirac (sodium salt) ()
Zomepiraco ()
Zomepirac sodium anhydrous ()
NSC-757379 ()
Zomaxin ()
Zopirac ()
Zomepirac sodium salt dihydrate ()
P&D ID
PD001718
CAS
64092-49-5
64092-48-4
33369-31-2
Tags
available
drug
Drug indication
Pain
rheumatic disease
Drug Status
approved
withdrawn
Max Phase
4.0
First approval
1980
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Zomepirac sodium salt (McN-2783-21-98) is a potent prostaglandin biosynthesis inhibitor. Zomepirac sodium salt is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac sodium salt can cause immune-mediated liver injury[1][2].
PRICE
29
DESCRIPTION
Zomepirac sodium salt (McN-2783-21-98) is a prostaglandin synthetase inhibitor.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
18
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
291.07
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.85
TPSA
59.3
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PDE2
PGE synthase
PTGDR2
MOA
prostaglandin synthesis inhibitor
ATC
M01AB04
Toxicity type
dermatological
Pathway
Immunology/Inflammation
Metabolism
Source data
